# A Study of WJ05129 in Advanced Malignant Solid Tumors

> **NCT05326035** · PHASE1,PHASE2 · TERMINATED · sponsor: **Suzhou Junjing BioSciences Co., Ltd.** · enrollment: 26 (actual)

## Conditions studied

- Locally Advanced or Metastatic Malignant Solid Tumors

## Interventions

- **DRUG:** WJ05129
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT05326035
- **Lead sponsor:** Suzhou Junjing BioSciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-12-26
- **Final completion:** 2023-12-26
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** The sponsor terminated the study on the basis of the current data and the company's research and development strategy
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05326035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05326035, "A Study of WJ05129 in Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05326035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*